1st Circuit Dupixent news shows skin cancer cases across Maine, Massachusetts, New Hampshire, and Rhode Island. While the full extent of lymphoma unmasking continues to emerge, MDL compensation is now being sought for eczema and asthma medication victims.
To learn more, please see our information on claiming a 1st Circuit Dupixent settlement.
Maine Dupixent News
Maine Dupixent news reports indicate widespread development or unmasking of T-Cell lymphoma.
- ME Dupixent News – Coming Soon / As Available
If you were diagnosed with skin cancer following eczema or asthma treatment, contact us about filing a Maine Dupixent lawsuit.
Massachusetts Dupixent News
Massachusetts Dupixent news reports indicate widespread development or unmasking of T-Cell lymphoma. If you were diagnosed with skin cancer following eczema or asthma treatment, contact us about filing a Massachusetts Dupixent lawsuit.
Massachusetts Research of Dupixent-CTCL in Atopic Dermatitis Patients
Massachusetts researchers examined the potential relationship between Dupixent and cutaneous T-cell lymphoma in atopic dermatitis (AD) patients.
The team included experts from leading medical institutions across Boston, Cambridge, and Worcester. Researchers analyzed FDA adverse-event reports submitted between 2017 and late 2023.
Dupixent showed a 30-fold proportional CTCL reporting ratio by AD patients compared with other medications. However, this reporting ratio does not establish individual cancer risk or prove causation.
Researchers also explored how interleukin signaling changes might unmask or accelerate existing CTCL. Their findings call for additional research and continued medical awareness.
Patients with atopic dermatitis should discuss persistent or worsening skin symptoms with a qualified healthcare provider.
👉 For additional details on the Massachusetts atopic dermatitis research, read the full Dupixent-CTCL news report on PubMed Central. (PubMed Central)
New Hampshire Dupixent News
New Hampshire Dupixent news reports indicate widespread development or unmasking of T-Cell lymphoma.
- NH Dupixent News – Coming Soon / As Available
If you were diagnosed with skin cancer following eczema or asthma treatment, contact us about filing a New Hampshire Dupixent lawsuit.
Rhode Island Dupixent News
Rhode Island Dupixent news reports indicate widespread development or unmasking of T-Cell lymphoma.
- RI Dupixent News – Coming Soon / As Available
If you were diagnosed with skin cancer following eczema or asthma treatment, contact us about filing a Rhode Island Dupixent lawsuit.
1st Circuit Dupixent News Supports MDL Settlement for Skin Cancer
1st Circuit Dupixent news of T-cell lymphoma has raised concerns for eczema and asthma patients in Maine, Massachusetts, New Hampshire, and Rhode Island. As such, public support is growing for the court’s certification of a Dupixent Multi-District Litigation (MDL) to administer claims.
Lymphoma Attorneys Act on 1st Circuit Dupixent News of Skin Cancer
Reporting skin cancer is an important first step to justice. If your family has been impacted by Dupixent, contact us about filing a 1st Circuit settlement claim.
For background information on T-cell lymphoma, please see our Dupixent lawyers homepage.